Leo and Co. want a partnership with the right pharma for each specific indication, they have repeated their desire to do partnerships repeatedly as evidenced in PR's and interviews, all well publicized on this board. They have reflected on the fact that they currently have more interest to do so than ever before in the Co.'s history. Leo the shrewd CPA businessman and BERTOLINO, MD, PHD, MBA, President and Chief Medical Officer are singing the same tune whenever asked while Menon remains the genius in the lab.
The key to the puzzle it seems to me is reflected in the latest OM trial. Pharma is interested in specific indications, the current P and OM trials would seem necessary and sufficient to satisfy their interests if the results continue to be both efficacious and safe. The UP 2b seems to me to be designed to quickly satisfy questions raised by interested pharma's as well as to inform the Co. in preparing the design of a potential registration trial. It also adds credibility to the value of B as a true franchise molecule with many indications and useful properties. I'm very curious to know if an interested pharma worked with Dr. B to design the trial to answer questions before partnering however I think it borders on being material disclosure and therefore better addressed in a PR. Maybe if you ask them they'll answer the question in their next PR. They are very good about answering emails but do not disclose material facts not previously made public.
2017 has been designated to be the year of partnerships, were entering the 2nd Q, I expect OM, UP and P to be the subject of serious partnership negations with outcomes to be informed by the upcoming trial results. I'm expecting at least one partnership this year and there is a good chance for two. Several posters on this board are doing a great job keeping us all informed and reminded about trial schedules and anticipated announcement time frames.
I'm not aware of any interest or any intent by the Co. to sell the entire co and I hope they don't as we are too early stage in regards to maximizing potential value.
